SOCS3 and chronic myelogenous leukemia, BCR-ABL1 positive: Takeuchi et al. suggested increased expression of SOCS3 in bone marrow cells may result from the action of several cytokines secreted in the bone marrow environment [17], so we speculated the bone marrow environment alteration caused by imatinib treatment may induce the up-regulation of SOCS3 in CML cells here.